Anshul Dhankher, an analyst from LifeSci Capital, maintained the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated price target remains the same with $17.00.
Anshul Dhankher has given his Buy rating due to a combination of factors related to Perspective Therapeutics’ recent developments and strategic direction. The company has initiated a new phase in its clinical trials, dosing the first patient in a lower dose cohort of its VMT01 monotherapy, which targets MC1R-positive metastatic melanoma. This strategic move is informed by previous trial data suggesting that lower doses might be more effective, potentially enhancing the immune response against tumors.
Additionally, Perspective Therapeutics is exploring the combination of VMT01 with nivolumab, an anti-PD-1 therapy, which could further clarify the efficacy and safety profile of VMT01. The company’s financial position, with approximately two years of cash runway, supports its ongoing research and development efforts. These factors, combined with the potential for improved therapeutic outcomes, underpin Dhankher’s optimistic outlook and Buy rating for the stock.
In another report released on April 8, Truist Financial also maintained a Buy rating on the stock with a $10.00 price target.